AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05756712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phase 1 Placebo
Description: Washout 72 hours and chew two tablets of placebo for phase 2 (day 4).
Study NCT05756712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phase 2 Placebo
Description: Chew two tablets of placebo for phase 1 (day 1)
Study NCT05756712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phase 2 Wonderlab Product
Description: Washout 72 hours and chew two tablets of Wonderlab Product for phase 2 (day 4).
Study NCT05633628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Periodic CGM group with data analysis report- Intervention group
Description: The patients are also instructed to continue to perform SMBG by finger prick if they experience symptoms of hypo- or hyperglycemia. During visit 0 (baseline) the patients is also instructed about how they can log in to the National Diabetes Register (NDR) to access their own NDR's recorded data and use the diabetes questionnaire.
Study NCT06783556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Ear Electroacupuncture of Battlefield Acupuncture (BFA) and paracetamol intravenous therapy
Description: Electroacupuncture therapy was performed 2 hours before PCNL surgery. Needle insertion was performed perpendicularly at the Battlefield Acupuncture (BFA) points of the ear, namely MA-IT1 Cingulate gyrus, MA-AT2 Thalamus, MA-H2 Omega2, MA-H1 Point Zero and MA-TF1 Shenmen bilaterally. Then the electrostimulator cable was connected to the ear acupuncture points MA-AT2 and MA-TF1 bilaterally on the same side and then fixed with plaster. Electroacupuncture uses continuous waves of 2 Hz frequency with an intensity that can be tolerated by the patient for 30 minutes.~Patients also received standard therapy with 1000 mg intravenous paracetamol with a maximum of 3 times administration per 24 hours and can be reduced according to the needs of the patient's pain complaints.
Study NCT06783556 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: The sham electroacupuncture and paracetamol intravenous therapy
Description: Sham electroacupuncture therapy was performed 2 hours before PCNL surgery. Needle only attached using plester (not inserted) at the Battlefield Acupuncture (BFA) points of the ear, namely MA-IT1 Cingulate gyrus, MA-AT2 Thalamus, MA-H2 Omega2, MA-H1 Point Zero and MA-TF1 Shenmen bilaterally. Then the electrostimulator cable was connected to the ear acupuncture points MA-AT2 and MA-TF1 bilaterally on the same side and then fixed with plaster. Electroacupuncture device is not turned on. The therapy is carried out for 30 minutes.~Patients also received standard therapy with 1000 mg intravenous paracetamol with a maximum of 3 times administration per 24 hours and can be reduced according to the needs of the patient's pain complaints.
Study NCT06782607 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pneumonia Panel by FilmArray
Description: The Pneumonia Panel comprehensively identifies 33 potential pathogen targets from sputum-like (including endotracheal aspirate) and bronchoalveolar lavage (BAL)-like (including mini-BAL) samples. For 15 of the bacteria, the Pneumonia Panel provides semi-quantitative results, which may help determine whether an organism is a colonizer or a pathogen.
Study NCT06784102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Damon Clear Debonding Plier (the primary intervention being tested in this study).
Description: This clinical trial evaluates two types of orthodontic debonding pliers: the Damon Clear Debonding Plier and the traditional Bracket Remover Debonding Plier. The Damon Clear plier features a third wedging arm, which applies an additional lingual or palatal force in addition to the standard occluso-gingival force. The study is designed to assess and compare pain levels and debonding forces between the two pliers. A total of 40 patients, aged 17-25, were treated with both devices using a split-mouth design. The Damon Clear Plier is tested on one side of the mouth while the Bracket Remover Plier is used on the opposite side. Pain perception was measured immediately after the debonding procedure using the Numerical Rating Scale (NRS), and the forces applied during debonding were measured with a force-sensitive prototype. The study aims to identify the device that provides effective debonding with less pain.
Study NCT06783543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive detumescence treatment with education video
Description: Comprehensive detumescence treatment, including skin care, manual lymphatic drainage, low elastic bandaging and functional exercise four steps
Study NCT06783543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive detumescence treatment
Description: Three to five times a week, one hour each time
Study NCT06787443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible subjects will receive Placebo to take daily for five weeks
Study NCT06787443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement with Proprietary Herbal Extract Blend and GABA
Description: Eligible subjects will receive active product to take daily for five weeks
Study NCT06784843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine as an adjuvant to local anesthesia for peribulbar block
Description: Dexmedetomidine as an adjuvant to a local anesthetic mixture (bupivacaine, lidocaine, and hyaluronidase) for peribulbar block during cataract surgery
Study NCT06784843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam as an adjuvant to local anesthesia for peribulbar block
Description: Midazolam as an adjuvant to a local anesthetic mixture (bupivacaine, lidocaine, and hyaluronidase) for peribulbar block during cataract surgery
Study NCT06785740 — intervention group
Intervention type: DRUG
Intervention: Statin
Description: Statin use
Study NCT06786403 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bromelain
Description: Dietary Supplement: Bromelain 1000 mg/day
Study NCT06786403 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1000 mg/day)
Study NCT06424899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
Study NCT06424899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adebrelimab
Description: This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
Study NCT06424899 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radical chemoradiotherapy
Description: The total dose of radiotherapy was 60 Gy ± 10% (54 Gy - 66 Gy). The minimum technical standard for radiotherapy is the three dimensional conformal radiotherapy (3D-CRT) planned by CT.
Study NCT06424899 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radical chemoradiotherapy
Description: The total dose of radiotherapy was 60 Gy ± 10% (54 Gy - 66 Gy). The minimum technical standard for radiotherapy is the three dimensional conformal radiotherapy (3D-CRT) planned by CT.
Study NCT06424899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum based chemotherapy
Description: Platinum based chemotherapy: Platinum drug must be one of cisplatin, carboplatin or nedaplatin; The other drug must contain one of the following: etoposide, vinorelbine, vinblastine, pemetrexed, taxanes (e.g., paclitaxel, docetaxel, albumin paclitaxel, paclitaxel liposomes) or gemcitabine (gemcitabine is not permitted in concurrent chemoradiotherapy regimens).
Study NCT06424899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum based chemotherapy
Description: Platinum based chemotherapy: Platinum drug must be one of cisplatin, carboplatin or nedaplatin; The other drug must contain one of the following: etoposide, vinorelbine, vinblastine, pemetrexed, taxanes (e.g., paclitaxel, docetaxel, albumin paclitaxel, paclitaxel liposomes) or gemcitabine (gemcitabine is not permitted in concurrent chemoradiotherapy regimens).
Study NCT05056181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Physical activity
Study NCT05520424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The Daily Supplement
Description: The ingredient list of the product includes the following:~400mg of curcumin (Longvida) 300mg of lemon balm extract (Cyracos) 200mg of American ginseng (Cereboost) 50mg of epigallocatechin gallate derived from green tea Organic oat milk powder Phosphatidylserine (SerinAid) (active) B6 (in the form of P5P) Folate (Quatrefolic) B12 Silica (non-active)
Study NCT04618991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filling the Quebec Sleep Questionnaire
Description: Filling the Quebec Sleep Questionnaire (QSQ) by the pre-surgery patient, then at 3 months post surgery and 1 year post surgery.
Study NCT06103071 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sweeping of membranes
Description: After informed consent all the patients in interventional group will have sweeping of membranes from 37 weeks of pregnancy . It will be repeated weekly till 40 weeks.
Study NCT06065189 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CS-101 injection
Description: Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
Study NCT05122780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angiography
Description: coronary angiography will be performed via the transradial or transfemoral approach with the use of a 6F sheath. Coronary angiography will be performed within 90 minutes from hospital admission in patients presenting with persistent ST-segment elevation, and within 48 hours in patients presenting with non-ST-segment elevation. Unfractionated heparin (initial weight-adjusted intravenous bolus of 60 IU/Kg, with repeat boluses to achieve an activated clotting time of 250 to 300 seconds) was administered in all patients. If evidence of plaque rupture
Study NCT05122780 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary angiography
Description: coronary angiography will be performed via the transradial or transfemoral approach with the use of a 6F sheath. Coronary angiography will be performed within 90 minutes from hospital admission in patients presenting with persistent ST-segment elevation, and within 48 hours in patients presenting with non-ST-segment elevation. Unfractionated heparin (initial weight-adjusted intravenous bolus of 60 IU/Kg, with repeat boluses to achieve an activated clotting time of 250 to 300 seconds) was administered in all patients. If evidence of plaque rupture
Study NCT05122780 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: OCT imaging
Description: OCT imaging will be performed in the culprit artery in all patients randomized to the precision medicine approach. A 0.014-inch guidewire will be placed distally in the target vessel and an intracoronary injection of 200 µg of nitroglycerine will be performed. Frequency domain OCT (FD-OCT) images are acquired by a commercially available system (C7 System, LightLab Imaging Inc/ St Jude Medical, Westford, MA) connected to an OCT catheter (C7 Dragonfly; LightLab Imaging Inc/ St Jude Medical, Westford, MA), which was advanced to the culprit lesion. The FD-OCT run will be performed using the integrated automated pullback device at 20 mm/s. During image acquisition, coronary blood flow will be replaced by continuous flushing of contrast media directly from the guiding catheter at a rate of 4 ml/s with a power injector in order to create a virtually blood-free environment.
Study NCT05122780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI):
Description: PCI with stent implantation will be considered in selected cases with evidences of plaque rupture
Study NCT05122780 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcholine provocative test
Description: ACh will be administered in a stepwise manner into the left coronary artery (LCA) (20-200 μg) or into the right coronary artery (RCA) (20-50 μg) over a period of 3 min with a 2-3 min interval between injections. Coronary angiography will be performed 1 min after each injection of these agents and/or when chest pain and/or ischaemic ECG shifts were observed. The decision of testing with provocative test LCA or RCA as first will be left to the discretion of the physicians; both LCA and RCA will be tested if the first test was negative. Angiographic responses during the provocative test will be assessed in multiple orthogonal views in order to detect the most severe narrowing and/or analysed by using computerized quantitative coronary angiography (QCA-CMS, Version 6.0, Medis-Software, Leiden, The Netherlands).
Study NCT05122780 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: TT-Echocardiography
Description: TT-Echo will be used to calculate left and right ventricular and atrial dimensions, left and right ventricular systolic function, transmitral flow Doppler spectra, mitral and tricuspidal valve annulus tissue Doppler spectra, ejection time and stroke volume, inferior vena cava, aorta and pulmonary artery diameters and Doppler spectra, according to the recommendations of the American Society of Echocardiography.
Study NCT05122780 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TT-Echocardiography
Description: TT-Echo will be used to calculate left and right ventricular and atrial dimensions, left and right ventricular systolic function, transmitral flow Doppler spectra, mitral and tricuspidal valve annulus tissue Doppler spectra, ejection time and stroke volume, inferior vena cava, aorta and pulmonary artery diameters and Doppler spectra, according to the recommendations of the American Society of Echocardiography.
Study NCT05122780 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: TE/contrast echocardiography
Description: In patients with angiographic evidence or suspicion of distal microembolization, TE-Echo consisting of an echocardiographic probe inserted in to the oesophagus will be used to detect a hidden cardioembolic source (i.e. left atrial thrombus); in patients with suspected left ventricular source of cardioembolism, contrast echocardiography consisting of a 0.3ml solution of SONOVUE will be used.
Study NCT05122780 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac magnetic resonance
Description: CMR will be performed during hospital stay on a 1.5-T system equipped with a 32-channel cardiac coil. Patients underwent conventional CMR including cine, T2-weighted, first pass perfusion, and conventional breath-held late gadolinium enhancement (LGE).
Study NCT05122780 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac magnetic resonance
Description: CMR will be performed during hospital stay on a 1.5-T system equipped with a 32-channel cardiac coil. Patients underwent conventional CMR including cine, T2-weighted, first pass perfusion, and conventional breath-held late gadolinium enhancement (LGE).
Study NCT05122780 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Circulating biomarkers
Description: Blood sampling for circulating biomarkers and miRNA expression profile at the time or within 12 hours of coronary angiography. Blood sampling will be processed and analysed in the research laboratory of the Department of Cardiovascular Science. Biological aliquots will be preserved at XBiogem Biobank at Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome (see section 33).
Study NCT05122780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet Drug
Description: acetylsalicylic acid (loading dose 250mg intravenously followed by 75mg orally) + P2Y12 receptor inhibitor (i.e. Clopidogrel, 300 or 600mg loading dose orally, followed by 75 mg orally daily).
Study NCT05122780 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Antiplatelet Drug
Description: acetylsalicylic acid (loading dose 250mg intravenously followed by 75mg orally) + P2Y12 receptor inhibitor (i.e. Clopidogrel, 300 or 600mg loading dose orally, followed by 75 mg orally daily).
Study NCT05122780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Description: i.e. atorvastatin; dosages titrated on the patient's clinical characteristics
Study NCT05122780 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Statin
Description: i.e. atorvastatin; dosages titrated on the patient's clinical characteristics
Study NCT05122780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blocker
Description: i.e. bisoprolol; dosages titrated on blood pressure, ECG, heart rate
Study NCT05122780 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Beta blocker
Description: i.e. bisoprolol; dosages titrated on blood pressure, ECG, heart rate
Study NCT05122780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACEi/ARB
Description: i.e. ramipril; dosages titrated on blood pressure, ECG, heart rate
Study NCT05122780 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ACEi/ARB
Description: i.e. ramipril; dosages titrated on blood pressure, ECG, heart rate
Study NCT05122780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CCB
Description: i.e. diltiazem; dosages titrated on blood pressure, ECG, heart rate
Study NCT05122780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrates
Description: i.e. nitroglycerine; dosages titrated on blood pressure, ECG, heart rate
Study NCT05122780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulant
Description: i.e. warfarin; the selection of the anticoagulant agent will be based on the clinical scenario, contraindications etc
Study NCT05087251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Five Psycho-educational Session(s)
Description: 5 psychoeducational sessions focused on skills for enhancing wellbeing, relationships, social support, and ability to cope with uncertainty
Study NCT05087251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One Psycho-educational Session(s)
Description: 1 session focused on exploring goals and expectations for post-treatment quality of life, including supportive listening; assessment of unmet needs; preferences for support, and tailored referral recommendations
Study NCT05051891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib and R-CHOP
Description: Orelabrutinib in Combinaion with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
Study NCT05051891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP
Description: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
Study NCT05621395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-OJ-01
Description: 1 capsule (400 mg) orally to be taken after breakfast daily for 60 days
Study NCT05621395 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose
Description: 1 capsule (400 mg) orally to be taken after breakfast daily for 60 days
Study NCT00975468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Controlled vs. Volume Controlled Ventilation during OLV
Description: Ventilation will be initiated with a tidal volume of 8 ml.kg-1 in Volume-controlled group and with a peak airway pressure that provided a tidal volume of 8 ml.kg-1 in pressure-controlled group. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
Study NCT00975468 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pressure Controlled vs. Volume Controlled Ventilation during OLV
Description: Ventilation will be initiated with a tidal volume of 8 ml.kg-1 in Volume-controlled group and with a peak airway pressure that provided a tidal volume of 8 ml.kg-1 in pressure-controlled group. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
Study NCT06373198 — intervention group
Intervention type: OTHER
Intervention: standard of care
Description: An evaluation of the positivity of the hepatitis C test will be carried out. Positive patients will be included in the follow-up and specific treatment will be requested to achieve a cure. Standard of care will be applied.
Study NCT05176938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided Thoracic Interfascial plane Block (TIFB)
Description: Patients of the group will be placed supine and elevate arm to the head, Serratus intercostal plane block will be with the probe in the midaxillary line, The subcutaneous tissue and serratus muscle will be identified in the superficial plane, whereas the external intercostal muscles will be identified in the intermediate plane and finally in the deep plane the ribs, pleura and lung will be identified. The needle will be advanced from caudal to cranial direction after giving 3 ml lidocaine locally. In-plane technique was used until the tip of the needle placed between the serratus anterior muscle and the external intercostals muscle a volume of 20 ml plain bupivacaine will be injected.
Study NCT05176938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided Erector Spinae plane Block (ESPB)
Description: The patient will be placed in setting position and a superficial (5-12 MHz) ultrasound transducer will be placed in a longitudinal orientation, 3 cm lateral to the T4 spinous process. An 8-cm 22-gauge spinal needle will be inserted in cephalic direction after giving 3 ml lidocaine locally until the needle tip hit the transverse process of T4 under ultrasound image visualization, then the needle will be withdrawn slowly to be within the interfacial plane below the erector spinae muscle, then the anesthetic mixture will be injected here. Successful injection will be evidenced by visible linear free spread (cranially and caudally) of injectate below the muscle.